Aletheian Wealth Advisors LLC Acquires 109 Shares of Eli Lilly and Company (NYSE:LLY)

Aletheian Wealth Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 13.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 918 shares of the company’s stock after buying an additional 109 shares during the period. Aletheian Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $831,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in LLY. Everpar Advisors LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $1,845,000. International Assets Investment Management LLC lifted its position in shares of Eli Lilly and Company by 5.3% during the fourth quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock valued at $7,343,000 after purchasing an additional 632 shares in the last quarter. AMJ Financial Wealth Management bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $201,000. GUNN & Co INVESTMENT MANAGEMENT INC. lifted its position in shares of Eli Lilly and Company by 124.7% during the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 1,438 shares of the company’s stock valued at $838,000 after purchasing an additional 798 shares in the last quarter. Finally, Providence First Trust Co bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $274,000. 82.53% of the stock is owned by institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,120,089 shares of company stock worth $990,278,343. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

LLY stock traded down $5.54 during midday trading on Wednesday, reaching $948.94. The company had a trading volume of 1,679,095 shares, compared to its average volume of 3,081,237. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The company has a market capitalization of $901.88 billion, a P/E ratio of 139.76, a P/E/G ratio of 1.81 and a beta of 0.41. The firm has a 50-day moving average price of $888.89 and a 200-day moving average price of $818.23.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.55%. Eli Lilly and Company’s payout ratio is 76.58%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Morgan Stanley reaffirmed an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. Argus lifted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Finally, Bank of America lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $961.76.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.